Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 939-420-2 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Specific investigations: other studies
Administrative data
Link to relevant study record(s)
Description of key information
A study in mice indicated that methyl isobutyl ketone (MIBK) may be an agonist for the constitutive androstane receptor (CAR) in liver mice. This was evaluated following inhalation exposure to 1800 ppm MIBK for 7 days. The study authors noted that this mechanism of action for liver carcinogenicity is not relevant to humans.
A study in rats, demonstrated that MIBK may exert effects on the male rat kidney via an alpha-2u-globulin mechanism. As well, this mecanism of action for kidney carcinogenicity, which is species and male specific, is not relevant to humans.
Additional information
The key studies for this group of substances (DIBC, DIBK, MIBK and MIBC) are two 2 -year carcinogenicity studies in mice and rats using MIBK. These studies showed the potential for MIBK to produce kidney tumours in rats and liver tumours in mice. Given the absence of any genotoxicity for this group of substances it was considered that the mode of action involved a non-genotoxic, threshold mechanism. In addition, the relevance of these tumour types to humans has been questioned due to the data available on the potential mode of action. The below studies were conducted to understand whether the mode of action for MIBK carcinogenicity in liver and kidney was in fact relevant for humans. In addition to these studies, additional data are also being generated to provide further support for the mechanism of tumour formation and its lack of relevance to humans.
Given the structural similarities and consistent toxicological profiles within this group of substances it is considered plausible that all members could produce toxicity in the livers and kidneys that may ultimately result in tumor formation in chronic studies. However, it therefore follows that their structural similarities and common metabolic pathways would also support a common mode of action, and thus the data that support a lack of human relevance for MIBK carcinogenicity also support the lack of relevance for the other members of the group.
Studies on the mode of action for carcinogenicity
In a non-guideline and non-GLP study, the effects of methyl isobutyl ketone (MIBK) on the mouse liver were evaluated (The Dow Chemical Company, 2009). Male B6C3F1 mice were implanted with 5-bromo-2’deoxyuridine (BrdU) pumps and then exposed to 0 or 1800 ppm (n=6/group) of MIBK via whole-body inhalation for 6 hours/day for 7 days. In-life assessments included clinical signs and body weights. Mice were euthanized and assessed for clinical chemistry, gene expression analysis of the upper third of the left liver lobe, liver histopathological examination and BrdU proliferation analysis, and liver enzyme activity. There were no treatment-related effects noted for clinical signs, body weights, liver weights, or clinical chemistry assessments. Treatment-related findings included very slight hepatocytes hypertrophy with increased cytoplasic eosinophilia in the centrilobular/midzonal regions of the hepatic lobule which were consistent with increased smooth endoplasmic reticulum and induction of cytochrome P450 enzymes. CYP2B10 transcript levels increased 4-fold and CYP4A10 decreased 5.56-fold. This was verified by increased CYP2B10 enzyme activity (PROD) and hepatocyte proliferation. These responses are commonly observed following activation of constitutive androstane receptor (CAR) and indicate that MIBK may be an agonist ligand for CAR in mice and share a similar mode of action to that of Phenobarbital in mice. The study authors noted that this mechanism of action is not relevant to humans.
In another non-guideline and non-GLP study, the effects of MIBK exposure on Fischer 344 rat kidneys were assessed (Borhoff et al., 2009). Male and female rats were administered corn oil, 1000 mg/kg bw/day MIBK, or d-limonene (positive control) for 10 consecutive days by oral gavage (4/sex/group). Rats were euthanized 24 hours after the last dose, and the left kidney evaluated for histological changes in hyaline droplet accumulation, alpha-2u- nephropathy, and proliferating cell nuclear antigen. The right kidney was assessed for total protein and alpha-2u-globulin using an enzyme-linked immunosorbent assay (ELISA). There were no changes in body weight gain, terminal body weights, or total kidney weight. The kidney:body weight ratio was increased slightly in male and female rats compared to controls. Changes observed in MIBK-treated male rats were similar or slightly milder than those observed in d-limonene-treated rats. Findings included mild to moderate hyaline droplet accumulation, positive Mallory’s Heidenhain staining, more intense alpha-2u-globulin staining compared to untreated controls, and a statistically significant increase in renal cell proliferation. There were no changes noted in any of the females administered MIBK. These results provide support that MIBK exerts renal effects in male rats through an alpha-2u-mediated mechanism. This mechanism of action is not considered relevant to human risk assessment.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.